Precision Cancer Consortium announces new industry member and leadership succession as it celebrates its one-year anniversary
WASHINGTON, April 14, 2023 /PRNewswire/ -- The Precision Cancer Consortium (PCC) is pleased to announce the addition of AstraZeneca as its newest member.
- WASHINGTON, April 14, 2023 /PRNewswire/ -- The Precision Cancer Consortium (PCC) is pleased to announce the addition of AstraZeneca as its newest member.
- Since its formation in April 2022, the PCC has driven a variety of initiatives aimed at increasing patient access to precision diagnostics using comprehensive genomic profiling (CGP), including next generation sequencing (NGS).
- Improved testing is critical to ensure physicians and their patients can better understand their disease and receive the most optimal treatment."
- The PCC is poised for a bright year ahead and to grow its impact to ensuring patient access to quality CGP testing to inform treatment selection."